About the Project
ULISES develops a disruptive, immunologic-based treatment strategy where cancer cells are reprogrammed to become “visible” to the patients’ immune system.
This breakthrough therapy will offer several advantages over current therapies: much greater efficiency; use of the patient’s own immune system to attack the cancerous cells; and fewer side effects meaning improved patient outcomes.
Our role
We are responsible for the design, coordination and implementation of communication and dissemination activities.
ICONS is also in charge of defining the exploitation strategy and planning.
